CTLT Stock Price, Chart, Stats & News

Catalent, Inc.
Save
11.52B
Market cap
–
Current P/E
–
Forward P/E
CTLT chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 21.75% |
Operating margin | -17.10% |
Pretax margin | -23.44% |
Net margin | -23.81% |
Effective tax rate | -1.56% |
ROA | -10.69% |
ROE | -25.32% |
D/E | 1.36x |
Interest coverage ratio | -2.95x |
CTLT valuation
P/E | – |
P/S | 2.63x |
P/B | 3.19x |
P/CF | 42.87x |
P/FCF | -195.29x |
P/OCF | 42.87x |
PEG | -0.19x |
EV multiple | -24.27x |
About
Catalent, Inc., operating globally through its various subsidiaries, specializes in the development and production of comprehensive solutions for a wide array of products, including pharmaceutical drugs, protein-based biologics, advanced cell and gene therapies, and consumer health items. The company's operations are strategically divided into four key segments: Biologics; Softgel and Oral Technologies; Oral and Specialty Delivery; and Clinical Supply Services. The Softgel and Oral Technologies division focuses on the formulation, development, and manufacturing of soft capsules.
Similar securities
Based on sector and market capitalization
Report issue











